Source: Annual Congress 2001 - Asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Bethke, K. Westphal, C. Weimar, M. David, K. Zech, W. Siegmund, W. Wurst (Konstanz, Greifswald). Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide. Eur Respir J 2001; 16: Suppl. 31, 1060

Member's Comments

No comment yet.

Related content which might interest you: No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Comparison of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone dipropionate in asthma control Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002 High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001 Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 42s Year: 2001 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011